An evidence synthesis approach to estimating Hepatitis C prevalence in England and Wales
- PMID: 19036917
- DOI: 10.1177/0962280208094691
An evidence synthesis approach to estimating Hepatitis C prevalence in England and Wales
Abstract
In England and Wales, routine monitoring has been consistently showing an increase in mortality and morbidity due to infection with the Hepatitis C Virus (HCV). However, the magnitude of the underlying epidemic is still the subject of debate. In this paper we present estimates of the number of individuals aged 15-59 chronically infected with HCV in 2003, derived from a Bayesian synthesis of information available from multiple sources on the size of the groups at risk for HCV and the risk specific anti-HCV prevalence. Results show that the number of chronic infections is of the order of 142,000 (95% CrI: 90,000, 231,000), with the majority (85%, 95% CrI: 74%, 93%) in injecting drug users and about 80% (95% CrI: 74%, 84%) in the age group 15-44.
Similar articles
-
Hepatitis C infection among injecting drug users in England and Wales (1992-2006): there and back again?Am J Epidemiol. 2009 Aug 1;170(3):352-60. doi: 10.1093/aje/kwp141. Epub 2009 Jun 22. Am J Epidemiol. 2009. PMID: 19546152 Free PMC article.
-
Hepatitis C prevalence in England remains low and varies by ethnicity: an updated evidence synthesis.Eur J Public Health. 2012 Apr;22(2):187-92. doi: 10.1093/eurpub/ckr083. Epub 2011 Jun 26. Eur J Public Health. 2012. PMID: 21708792
-
Projecting severe sequelae of injection-related hepatitis C virus epidemic in the UK. Part 2: Preliminary UK estimates of prevalent injection-related hepatitis C carriers, and derivation of progression rates to liver cirrhosis by gender and age at hepatitis C virus infection.J Epidemiol Biostat. 2001;6(3):267-77; discussion 279-85. J Epidemiol Biostat. 2001. PMID: 11437089
-
How many people in England and Wales risk infection from injecting drug use?Commun Dis Rep CDR Rev. 1995 Mar 3;5(3):R40-4. Commun Dis Rep CDR Rev. 1995. PMID: 7536591 Review.
-
The epidemiology of hepatitis C among injecting drug users in Belgium.Acta Gastroenterol Belg. 2005 Jan-Mar;68(1):50-4. Acta Gastroenterol Belg. 2005. PMID: 15832588 Review.
Cited by
-
Risk factors and genotype distribution of hepatitis C virus in Georgia: A nationwide population-based survey.PLoS One. 2022 Jan 21;17(1):e0262935. doi: 10.1371/journal.pone.0262935. eCollection 2022. PLoS One. 2022. PMID: 35061841 Free PMC article.
-
Frequency, factors and costs associated with injection site infections: findings from a national multi-site survey of injecting drug users in England.BMC Infect Dis. 2008 Sep 18;8:120. doi: 10.1186/1471-2334-8-120. BMC Infect Dis. 2008. PMID: 18801177 Free PMC article.
-
Estimating the prevalence of hepatitis C infection in New York City using surveillance data.Epidemiol Infect. 2014 Feb;142(2):262-9. doi: 10.1017/S0950268813000952. Epub 2013 May 9. Epidemiol Infect. 2014. PMID: 23657093 Free PMC article.
-
Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.Clin Infect Dis. 2013 Aug;57 Suppl 2(Suppl 2):S39-45. doi: 10.1093/cid/cit296. Clin Infect Dis. 2013. PMID: 23884064 Free PMC article.
-
Hepatitis C infection among injecting drug users in England and Wales (1992-2006): there and back again?Am J Epidemiol. 2009 Aug 1;170(3):352-60. doi: 10.1093/aje/kwp141. Epub 2009 Jun 22. Am J Epidemiol. 2009. PMID: 19546152 Free PMC article.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
